Several researchers attempted to develop MRD tools to evaluate FLT3-ITD kinetics in AML, but the applicability of this approach was limited because of low sensitivity, and the necessity to design patient-specific assays based on the length of nucleotide inserts (47). This evidence concerns the gene FLT3 and acute myeloid leukemia.